Health

WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months

UN agencies are also calling for a meeting with Indian drug controller generals to discuss this issue 10:12

Representation image by PTI

New Delhi: WHO rejected the Indian Serum Institute’s proposal to extend the shelf life of Oxford-AstraZeneca COVID-19 (new coronavirus infection) Vaccines, Covishield, 6-9 months, citing inadequate data, sources said.

WHO is also seeking a meeting with the Indian Drug Controller General (DCGI) to discuss this issue, they said.

The move also occurs when Indian drug regulators extend the shelf life of Covishield from 6 to 9 months from the date of manufacture.

In a recent communiqué with the Pune-based Serum Institute of India (SII), WHO has also prescribed doses with sufficient titer or implemented higher specifications at the time of release, with a minimum specification of 2.5 x 108ifu /. I asked the company to get the dose. Filled throughout shelf life.

Shelf life is the length of time that an item remains suitable for use.

DCGI, a letter to SII in February, stated that there was no objection to “extending the shelf life of the Covishield vaccine” in multi-dose glass vials (10 doses-5 ml) from 6 to 9 months. I did.

“It is permitted to apply a shelf life of 9 months to unlabeled vials on hand, but such inventory details must be submitted batch by batch to this office and the Central Pharmaceutical Research Institute in Kasauli. There is. “DCGI Dr VG Somani said in a letter.

DCGI decisions help health authorities reduce vaccine waste.

AstraZeneca’s shelf life, according to the latest information from UK drug regulators dated February 22 COVID-19 (new coronavirus infection) The vaccine is 6 months old.

Meanwhile, European Union health agencies have concluded a “potential link” between vaccines and rare blood clots, but highlighted the benefits of vaccines for prevention, raising concerns about vaccines. COVID-19 (new coronavirus infection) Continue to outweigh the risks.

UK drug regulators said Wednesday that “evolving evidence” would link the Oxford-AstraZeneca vaccine to rare blood clots, providing an alternative to vaccines under the age of 30.

Developed by Oxford University and AstraZeneca, a leading Swedish and British pharmaceutical company, Covishield is manufactured by SII.

WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months Source link WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months

Related Articles

Back to top button